1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophyautonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, primary dysautonomia, vascular disorderActive, not recruitingPhase 32025-09-05NCT05696717